Skip to Main Content

PART 1 FIRST-IN-CLASS AGENTS

The FDA approved 40 new drugs and biologics of note in 2013. Twenty-two are pharmacologically similar to others already marketed and 10 are newly licensed biologics (see part 2 of this series). The remainder represent eight first-in-class agents indicated for the management of cancer, diabetes, hepatitis C infection, hypercholesterolemia, multiple sclerosis, and pulmonary hypertension (eTable 1). Three drugs, ibrutinib (IMBRUVICA) for lymphoma (eTable 1), obinutuzumab (GAZYVA) for chronic lymphocytic leukemia (see part 2 of this series), and sofosbuvir (SOVALDI) for hepatitis C infection (eTable 1), were the first drugs to be approved under FDA's "breakthrough therapy" designation.1 Established in 2012, FDA reserves breakthrough designations for drugs exhibiting superior efficacy against serious diseases.

eTable 1.New Pharmacological Drug Classes Introduced in 2013

Among previously approved drugs, one product, pertuzumab (PERJETA), became the first FDA-approved neoadjuvant treatment for breast cancer.2 Neoadjuvant treatments are given as a first step to shrink a tumor before the main treatment (usually surgery) is given. Another new product, clinolipid (see part 2 of this series) was granted a priority review to help alleviate the long-standing national ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.